COMPASS Pathways plc
Moat Score — COMPASS Pathways plc
Total Moat Score
12 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | COMP360 holds FDA Breakthrough Therapy designation and a National Priority Voucher, backed by two positive Phase 3 trials (COMP005, COMP006) in TRD and a proprietary polymorphic crystalline psilocybin formulation, giving COMPASS the most mature regulatory and IP position in the psychedelic-therapy category. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | The company outsources all manufacturing to CDMOs, historically relied on a single API supplier, and has no scale-driven cost edge; as a pre-revenue clinical-stage biotech it has no demonstrated cost advantage over rivals. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Breakthrough Therapy status and severe unmet need in TRD suggest potential pricing leverage once approved, but with no approved product, no payer negotiations completed, and DEA rescheduling still pending, pricing power is unproven. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | No classic network effect exists; the growing web of healthcare-delivery, digital-health, and academic Centers of Excellence partnerships builds delivery capacity and relationships but does not create value that compounds with each additional user. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | An in-clinic, therapist-supported psychedelic protocol could create meaningful provider and patient switching costs once established, but with no approved product yet and rivals like Usona and GH Research advancing similar modalities, this advantage remains largely theoretical. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | COMPASS is furthest along in a large, underserved TRD market and may enjoy first-mover efficient-scale dynamics if it launches ahead of psilocybin rivals such as Usona, but the market is large enough and several well-funded competitors are advancing in parallel, limiting a durable scale moat. |